A complete response letter was issued by the FDA to Mylan regarding its marketing application for a biosimilar of Amgen's Neulasta, or pegfilgrastim. The letter said more data on manufacturing, controls and chemistry from Mylan's research partner, Biocon, was necessary.
Mylan's Neulasta biosimilar turned down by FDA
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.